Locations:
Search IconSearch

Elegant Procedure Preserves Teen’s Vision and Self-Confidence

Growing tumor sparks concern for melanoma

Mystery Eye

A 16-year-old girl presented to Cleveland Clinic with a growing pigmented lesion of the left iris that was initially noted 5 years earlier. The girl’s visual acuity was 20/20 in the left eye, but her examination was remarkable for a 2- x 1.2- x 1-mm pigmented lesion in the 5 o’clock position with pupillary margin involvement.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The ongoing growth of the lesion was confirmed by comparing the appearance of the affected eye with earlier photographs of the patient.

Initial examination reveals a pigmented lesion with pupillary margin involvement.

“The examination findings and changing appearance of the nevus were concerning for iris melanoma, a diagnosis that must be confirmed by biopsy,” explains Arun Singh, MD, Director of the Department of Ophthalmic Oncology in the Cole Eye Institute. “In this case, our principal challenges included removing the tumor completely and with clear margins, protecting the patient’s vision and appearance, reconstructing the pupil and restoring ocular function.”

Following a discussion of treatment options, the patient agreed to undergo an excisional biopsy of the lesion. Using a minimally invasive approach, Dr. Singh performed an iridectomy and pupilloplasty to reconstruct the delicate tissue of the iris and recreate an appropriately sized pupil.

Novel surgical approach minimizes complications

Conventionally, iris resection for a suspected malignancy has involved a large incision in the cornea and sclera and the removal of 25% or more of the iris. This sector iridectomy has been associated with increased risk of wound-related complications, tumor seeding and recurrence, and photophobia due to iris defects.

Approximately 15 years ago, Dr. Singh developed a new technique: small-incision guarded hydroaspiration (SINGH procedure). Instead of one large incision, this approach involves multiple small incisions. After excising the tumor, plastic tubing containing a sodium hyaluronate solution is inserted into the anterior chamber. Using a syringe, the excised lesion is pulled into the tube, where it is isolated and removed safely as the tube is withdrawn from the anterior chamber. This prevents the tumor from being pulled across the wound, possibly shedding cells and seeding the edges of the wound.

Advertisement

The next step, pupilloplasty, restores the iris to a near-normal shape using a suturing slip-knot technique. This restoration of the iris not only repairs the cosmetic defect but also helps prevent photophobia.

“The larger incisions required by conventional techniques led to a number of risks that can now be avoided,” says Dr. Singh. “This minimally invasive approach results in faster healing and much better functional and cosmetic outcomes.”

Biopsy reveals benign growth

Histopathology demonstrated a densely pigmented lesion with a fair amount of cytoplasm and no mitotic activity. These findings were consistent with melanocytoma, a benign, deeply pigmented tumor that most commonly arises on or adjacent to the optic nerve head. Such growths most commonly arise on or adjacent to the optic nerve head; however, they often appear on the iris of younger patients.

“We always approach these kinds of cases with caution because the goal is to remove the entire tumor without compromising the patient’s vision,” explains Dr. Singh. “In this particular case, the stakes were somewhat elevated because the patient was so young, and our ability to restore the external appearance of the eye was one of her chief concerns.”

At one-week follow-up, the patient’s eye was healing well, and her visual acuity was 20/20 in the left eye.

Stitches are still visible at one-week follow-up, but the patient’s eye appeared to be healing properly.

At three month follow-up, the patient’s visual acuity and ocular pressures were stable, and her eye had a normal cosmetic appearance.

Advertisement

Virtually no signs of the tumor were visible three months after the procedure.

“If this patient would have come to us two decades ago, our best option would be to simply watch the lesion while hoping to avoid a big surgery,” says Dr. Singh. “Thanks to the development of these minimally invasive techniques, we were able to treat her safely and with great success.”

Advertisement

Related Articles

Dr. Mukhejee and colleagues
January 22, 2026/Cancer/News & Insight
Rare Cancers and Blood Disease Program Accelerates Diagnostic Journey

Multidisciplinary teams bring pathological and clinical expertise

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Ad